and how to treat sarcoidosis, the principles of treatment and stepwise algorithms will be critically appraised [13, 14]. The pipeline drugs on the horizon and ongoing clinical trials will be presented in a dedicated chapter [14]. Another novel and major element is represented by highlighting the patient’s perspective. Besides a chapter exploring non-organ-related symptoms like fatigue and cognitive impairment [15], which all belong to the clinical picture of sarcoidosis, a chapter covering the effects of the disease on quality of life and an overview of tools used to assess quality of life is presented separately [16]. We have tried to include the voices of clinicians, basic scientists and patients to provide a better insight into this many-faceted insidious disorder. We believe that readers around the world will find this book helpful. References 1 Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med 2020 26: 527–534. 2 Drent M, Costabel U, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2005. 3 Cozier YC, Arkema EV, Rodriguez JV, et al. Epidemiology: solving the jigsaw puzzle. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 8–24. 4 Spagnolo P, Grunewald J. Aetiopathogenesis, molecular determinants and immunological features. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 25–40. 5 van Moorsel CHM, Petrek M, Rivera NV. Unravelling the genetic basis of sarcoidosis. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 41–56. 6 James WE, Bonella F. Pulmonary sarcoidosis. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 122–141. 7 Birnie DH, Kouranos V. Cardiac sarcoidosis. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 142–159. 8 Tavee J, Voortman M. Granulomatous and nongranulomatous neurological sarcoidosis. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 160–173. 9 Murphy C, Marcoval J, Mañá J, et al. Cutaneous sarcoidosis. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 174–192. 10 Rossi G, Farver C. Pathological features and differential diagnosis. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 91–106. 11 Mostard RLM, Yadav R. Conventional and nuclear imaging techniques. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 75–90. 12 Korenromp IHE, Maier LA, Grutters JC. Serum and imaging biomarkers. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 107–121. 13 Culver DA, Wells AU. When to treat sarcoidosis. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 316–327. 14 Caliskan C, Prasse A. Treating sarcoidosis and potential new drugs. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 328–336. 15 Kahlmann V, Patel DC, Marts LT, et al. Non-organ-specific manifestations. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 206–222. 16 Tully T, Judson MA, Patel AS, et al. Quality-of-life assessment. In: Bonella F, Culver DA, Israël-Biet D, eds. Sarcoidosis (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 337–349. Disclosures: F. Bonella reports receiving the following, outside the submitted work: consulting fees from Boehringer Ingelheim, Roche and Galapagos payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Boehringer Ingelheim, Roche and BMS and support for attending meetings and/or travel from Boehringer Ingelheim, Savara and Roche. F. Bonella reports participation in data safety monitoring boards or advisory boards for GSK. D.A. Culver reports receiving the following during the past 36 months: grants/fees to his institution from Boehringer Ingelheim, Genentech, Mallinkrodt, aTyr, the Foundation for Sarcoidosis Research, the Ann Theodore Foundation and the National Heart, Lung and Blood Institute consulting https://doi.org/10.1183/2312508X.10000622 xi